MXPA06010715A - Anticuerpo del receptor del factor de crecimiento humano anti-epidermico. - Google Patents
Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.Info
- Publication number
- MXPA06010715A MXPA06010715A MXPA06010715A MXPA06010715A MXPA06010715A MX PA06010715 A MXPA06010715 A MX PA06010715A MX PA06010715 A MXPA06010715 A MX PA06010715A MX PA06010715 A MXPA06010715 A MX PA06010715A MX PA06010715 A MXPA06010715 A MX PA06010715A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- egfr
- growth factor
- factor receptor
- epidermal growth
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La Presente invencion provee un anticuerpo completamente humano que se enlaza al EGFR humano con una afinidad comparable o superior a IMC-C225, y que neutraliza la activacion de EGFR. Los anticuerpos de cadena simple, anticuerpos de cadena simple multivalentes, anticuerpos de dominios dobles, triples y sencillos. La invencion ademas provee acidos nucleicos y celulas anfitrionas y animales que codifican y expresan esos anticuerpos. La invencion ademas proporciona un metodo para neutralizar la activacion de EGFR, el tratamiento en un mamifero con crecimiento neoplasico y enfermedades hiperproliferativas no cancerosas usando los anticuerpos solos o en combinacion con otros agentes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55455504P | 2004-03-19 | 2004-03-19 | |
US62426404P | 2004-11-02 | 2004-11-02 | |
PCT/US2005/009583 WO2005090407A1 (en) | 2004-03-19 | 2005-03-21 | Human anti-epidermal growth factor receptor antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06010715A true MXPA06010715A (es) | 2007-05-23 |
Family
ID=34964896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06010715A MXPA06010715A (es) | 2004-03-19 | 2005-03-21 | Anticuerpo del receptor del factor de crecimiento humano anti-epidermico. |
Country Status (18)
Country | Link |
---|---|
US (1) | US7598350B2 (es) |
EP (2) | EP1735348B1 (es) |
JP (1) | JP4734319B2 (es) |
CN (1) | CN103007279B (es) |
AU (1) | AU2005224267B2 (es) |
CA (1) | CA2560305C (es) |
CY (2) | CY1113037T1 (es) |
DK (1) | DK1735348T3 (es) |
ES (1) | ES2387809T3 (es) |
HU (1) | HUS000495I2 (es) |
LT (1) | LTC1735348I2 (es) |
LU (1) | LU93093I2 (es) |
MX (1) | MXPA06010715A (es) |
NL (1) | NL300819I2 (es) |
PL (1) | PL1735348T3 (es) |
PT (1) | PT1735348E (es) |
RU (1) | RU2402569C2 (es) |
WO (1) | WO2005090407A1 (es) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
RU2294761C2 (ru) * | 1999-05-14 | 2007-03-10 | Имклон Систимс Инкопэритид | Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса |
CA2418083A1 (en) * | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
CN102584997A (zh) * | 2002-11-08 | 2012-07-18 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子-α的单结构域抗体及其用途 |
EP1558646A2 (en) * | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses thereof |
US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
CA2505326A1 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
EP1622941A2 (en) * | 2003-03-20 | 2006-02-08 | ImClone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
WO2007092453A2 (en) * | 2006-02-03 | 2007-08-16 | Imclone Systems Incorporated | Igf-ir antagonists as adjuvants for treatment of prostate cancer |
CN101058609B (zh) * | 2006-05-26 | 2011-04-13 | 神州细胞工程有限公司 | 人源抗体及其表达 |
KR20090021298A (ko) * | 2006-06-14 | 2009-03-02 | 임클론 시스템즈 인코포레이티드 | 항-egfr 항체의 동결건조 제제 |
CA2664327A1 (en) * | 2006-09-15 | 2008-03-20 | Lifescience Pharmaceuticals | Method for detecting and treating skin disorders |
US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
WO2009067242A2 (en) * | 2007-11-20 | 2009-05-28 | Imclone Llc | Co-crystal of antibody 11f8 fab fragment and egfr extracellular domain and uses thereof |
DK2769991T3 (en) * | 2008-01-03 | 2018-12-10 | Scripps Research Inst | ANTIBODY TARGETING WITH A MODULAR RECOGNITION AREA |
WO2009105557A1 (en) * | 2008-02-20 | 2009-08-27 | Arizona Biomedical Research Commission | Use of therapeutic peptides for the treatment and prevention of cancer |
CN102170907A (zh) * | 2008-08-05 | 2011-08-31 | 东丽株式会社 | 用于治疗和预防癌症的药物组合物 |
KR20160039295A (ko) | 2008-08-05 | 2016-04-08 | 도레이 카부시키가이샤 | 암의 검출 방법 |
BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
KR101108642B1 (ko) * | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
CN101875696B (zh) | 2009-11-11 | 2012-02-08 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗体及其制备方法与应用 |
CN101875695B (zh) * | 2009-11-11 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | 一种抗体及其编码基因与应用 |
CN101704891B (zh) | 2009-11-11 | 2011-11-09 | 中国人民解放军军事医学科学院生物工程研究所 | 一种针对表皮生长因子受体的抗体及其编码基因与应用 |
SG181707A1 (en) * | 2009-12-18 | 2012-07-30 | Sanofi Sa | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
ES2540858T3 (es) | 2010-02-04 | 2015-07-14 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención de cáncer |
MX2012008991A (es) | 2010-02-04 | 2012-09-07 | Toray Industries | Medicamento para tratar y/o prevenir el cancer. |
ES2583627T3 (es) | 2010-02-04 | 2016-09-21 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
PL2532366T3 (pl) | 2010-02-04 | 2017-02-28 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi |
US8911740B2 (en) | 2010-02-04 | 2014-12-16 | Toray Industries, Inc. | Pharmaceutical composition for treating and/or preventing cancer |
WO2012018260A1 (en) * | 2010-08-05 | 2012-02-09 | Universiteit Utrecht Holding B.V. | Epidermal growth factor receptor targeted immune therapy |
JP6121904B2 (ja) | 2010-09-08 | 2017-04-26 | ハロザイム インコーポレイテッド | 条件的活性治療用タンパク質を評価および同定する、または発展させる方法 |
KR101273918B1 (ko) | 2010-09-17 | 2013-06-13 | 강원대학교산학협력단 | 인간 항-상피세포성 성장인자수용체 Fab 항체 및 이를 포함하는 종양 치료용 약학 조성물 |
US10066004B2 (en) | 2010-10-12 | 2018-09-04 | Arizona Cancer Therapeutics, Llc | EGFR-based inhibitor peptides for combinatorial inactivation of ERBB1, ERBB2, and ERBB3 |
WO2012051247A2 (en) | 2010-10-12 | 2012-04-19 | Arizona Biomedical Research Commission | Egfr-based peptides |
CN103328505B (zh) | 2010-10-29 | 2015-12-02 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
BR112013010544A2 (pt) * | 2010-10-29 | 2016-08-02 | Immunogen Inc | moléculas de ligação ao egfr e imunoconjugados das mesmas |
US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
US20130122024A1 (en) | 2011-04-21 | 2013-05-16 | Bayer Intellectual Property Gmbh | New binder-drug conjugates (adcs) and use thereof |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
JP6065591B2 (ja) | 2011-08-04 | 2017-01-25 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
JP6003650B2 (ja) | 2011-08-04 | 2016-10-05 | 東レ株式会社 | 膵臓癌の治療及び/又は予防用医薬組成物 |
EP2741085B1 (en) | 2011-08-04 | 2017-04-05 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
MX348578B (es) | 2011-08-04 | 2017-06-20 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. |
JP6070191B2 (ja) | 2011-08-04 | 2017-02-01 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
WO2013018892A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
DK2740798T3 (en) | 2011-08-04 | 2017-03-06 | Toray Industries | Drug composition for cancer treatment and / or prevention |
SG11201402343SA (en) | 2011-11-21 | 2014-06-27 | Immunogen Inc | Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
PT2824114T (pt) | 2012-02-21 | 2019-08-05 | Toray Industries | Composição farmacêutica para o tratamento do cancro |
BR112014021102A2 (pt) | 2012-02-21 | 2021-12-28 | Toray Industries | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
HUE046788T2 (hu) | 2012-02-21 | 2020-03-30 | Toray Industries | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére |
JP6187255B2 (ja) | 2012-02-21 | 2017-08-30 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
BR112014023937A2 (pt) | 2012-03-30 | 2018-04-17 | Toray Industries | composição farmacêutica, agente farmacêutico de combinação e método de tratamento |
JP6107655B2 (ja) | 2012-03-30 | 2017-04-05 | 東レ株式会社 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
EP2850105A4 (en) * | 2012-05-17 | 2016-03-16 | Sorrento Therapeutics Inc | ANTIGENIC BINDING PROTEINS BINDING TO EGFR |
JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Egfr結合性ペプチド |
AU2013291051C1 (en) | 2012-07-19 | 2019-07-04 | Toray Industries, Inc. | Cancer detection method |
PL2876446T3 (pl) | 2012-07-19 | 2019-06-28 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
EP2877572B1 (en) | 2012-07-24 | 2018-11-28 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
EP2879712B1 (en) | 2012-07-31 | 2018-04-25 | Crown Bioscience, Inc. (Taicang) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
EP2890720B1 (en) * | 2012-08-30 | 2019-07-17 | The General Hospital Corporation | Compositions and methods for treating cancer |
CN102993305B (zh) * | 2012-11-16 | 2015-05-13 | 上海赛伦生物技术有限公司 | 人源抗人表皮生长因子受体抗体及其编码基因与应用 |
RU2652880C2 (ru) | 2013-04-07 | 2018-05-03 | Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. | Антитело против рецептора эпидермального фактора роста |
US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
TR201819812T4 (tr) | 2013-08-09 | 2019-01-21 | Toray Industries | Kanserin Tedavisi Ve/Veya Önlenmesi Amacına Yönelik Farmasötik Bileşim |
CA2922562A1 (en) | 2013-09-12 | 2015-03-19 | Halozyme, Inc. | Modified anti-epidermal growth factor receptor antibodies and methods of use thereof |
AU2014368449C1 (en) | 2013-12-20 | 2021-05-06 | Intervet International B.V. | Canine antibodies with modified CH2-CH3 sequences |
DK3086814T3 (da) | 2013-12-23 | 2020-09-14 | Bayer Pharma AG | Binder-konjugater (adcs) med ksp-inhibitorer |
CN111499753B (zh) | 2014-03-03 | 2022-10-21 | 高雄医学大学 | 双功能抗体及其用途 |
EP3172231B1 (en) * | 2014-07-24 | 2021-05-05 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
CN108251431B (zh) | 2015-03-05 | 2020-12-08 | 北京百特美博生物科技有限公司 | 双载体系统及其用途 |
TW201703769A (zh) | 2015-05-08 | 2017-02-01 | 美國禮來大藥廠 | 用於癌症的組合療法 |
JP6971858B2 (ja) | 2015-06-22 | 2021-11-24 | バイエル ファーマ アクチエンゲゼルシャフト | 酵素開裂性基を有する抗体薬物複合体(adc)および抗体プロドラッグ複合体(apdc) |
CA2990300A1 (en) | 2015-06-23 | 2016-12-29 | Hans-Georg Lerchen | Site specific homogeneous conjugates with ksp inhibitors |
TW201716439A (zh) | 2015-07-20 | 2017-05-16 | 美國禮來大藥廠 | Her3抗體 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
WO2017160568A1 (en) | 2016-03-16 | 2017-09-21 | Eli Lilly And Company | Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer |
CN108883195A (zh) | 2016-03-24 | 2018-11-23 | 拜耳制药股份公司 | 具有酶促可裂解基团的细胞毒性活性物质的前药 |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
CN110036030A (zh) * | 2016-09-26 | 2019-07-19 | 英克隆有限责任公司 | 癌症的组合疗法 |
JP7174704B2 (ja) | 2016-12-21 | 2022-11-17 | バイエル・アクチエンゲゼルシヤフト | 酵素開裂基を有する細胞毒性活性剤のプロドラッグ |
IL291308B1 (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
JP7072792B2 (ja) * | 2017-12-11 | 2022-05-23 | 国立大学法人神戸大学 | 二重特異性抗体 |
KR20210116437A (ko) | 2018-11-20 | 2021-09-27 | 코넬 유니버시티 | 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도 |
EP3954707A1 (en) * | 2018-12-21 | 2022-02-16 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Protease cleavable bispecific antibodies and uses thereof |
CA3154522A1 (en) | 2019-10-15 | 2021-04-22 | Christopher Carl Frye | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
CN113527482B (zh) * | 2020-04-17 | 2023-07-21 | 珠海泰诺麦博制药股份有限公司 | 抗人神经生长因子的抗体 |
JP2023536665A (ja) * | 2020-08-05 | 2023-08-28 | オハイオ・ステイト・イノベーション・ファウンデーション | アダプターポリペプチドおよびその使用方法 |
JP2023545681A (ja) | 2020-09-30 | 2023-10-31 | インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ | Egfrを標的とするキメラ抗原受容体 |
WO2022140670A2 (en) * | 2020-12-23 | 2022-06-30 | Phenomic Ai | Anti-activin antibodies and methods of using the same |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
FR2388385B1 (fr) * | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4510924A (en) * | 1980-07-10 | 1985-04-16 | Yale-New Haven Hospital, Inc. | Brachytherapy devices and methods employing americium-241 |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
US4846782A (en) * | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4763642A (en) * | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
ATE119198T1 (de) | 1988-04-16 | 1995-03-15 | Celltech Ltd | Verfahren zur herstellung von proteinen mittels rekombinanter dna. |
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6384191B1 (en) * | 1989-07-06 | 2002-05-07 | Regents Of The University Of California | Receptors for fibroblast growth factors |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
EP0525109A4 (en) | 1990-04-16 | 1993-06-30 | Rhone-Poulenc Rorer International (Holdings) Inc. | Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
ATE255131T1 (de) * | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5559235A (en) * | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
PT1696031E (pt) | 1991-12-02 | 2010-06-25 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
DK0672142T3 (da) * | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
US5550114A (en) * | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
US6811779B2 (en) * | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
CZ288955B6 (cs) * | 1994-02-23 | 2001-10-17 | Pfizer Inc. | Substituované chinazolinové deriváty, jejich pouľití a farmaceutické prostředky na jejich bázi |
AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
RU2170257C2 (ru) * | 1994-03-17 | 2001-07-10 | Мерк Патент Гмбх | Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли |
JP3249007B2 (ja) * | 1994-03-17 | 2002-01-21 | 富士通株式会社 | 半導体装置、その特性評価方法及び設計方法 |
US5656655A (en) * | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
US5869465A (en) * | 1994-04-08 | 1999-02-09 | Receptagen Corporation | Methods of receptor modulation and uses therefor |
US5468754A (en) * | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
US5604233A (en) * | 1994-04-28 | 1997-02-18 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
MX9707453A (es) | 1995-03-30 | 1997-12-31 | Pfizer | Derivados de quinazolina. |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5663144A (en) * | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
US5726181A (en) * | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
PT888349E (pt) * | 1996-01-23 | 2002-10-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
US5925566A (en) * | 1996-06-06 | 1999-07-20 | University Of Massachusetts | Non-activated receptor complex proteins and uses thereof |
JP2000512990A (ja) | 1996-06-24 | 2000-10-03 | ファイザー・インク | 過増殖性疾患を処置するためのフェニルアミノ置換三環式誘導体 |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
CA2271157A1 (en) | 1997-02-05 | 1998-08-06 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
US5914269A (en) * | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
PL348634A1 (en) | 1998-05-15 | 2002-06-03 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
AU763669B2 (en) | 1998-09-29 | 2003-07-31 | Wyeth Holdings Corporation | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors |
US6344455B1 (en) | 1998-11-19 | 2002-02-05 | Warner-Lambert Company | N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, and irreversible inhibitor of tyrosine kinases |
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
RU2294761C2 (ru) * | 1999-05-14 | 2007-03-10 | Имклон Систимс Инкопэритид | Лечение резистентных опухолей человека антагонистами рецепторов фактора роста эпидермиса |
DK2067788T3 (da) | 1999-05-18 | 2015-10-19 | Dyax Corp | Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf |
PT1210115E (pt) * | 1999-08-27 | 2009-11-12 | Genentech Inc | Dosagens para tratamento com anticorpos anti-erbb2 |
CA2418083A1 (en) | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
CA2422881A1 (en) * | 2000-10-13 | 2002-04-18 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
AU2002239486A1 (en) * | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
US20040116330A1 (en) * | 2001-04-27 | 2004-06-17 | Kenichiro Naito | Preventive/therapeutic method for cancer |
IL159225A0 (en) * | 2001-06-13 | 2004-06-01 | Genmab As | Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
BR0307216A (pt) * | 2002-01-28 | 2005-12-20 | Medarex Inc | Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma) |
EP2298346A3 (en) | 2002-03-04 | 2011-11-16 | Imclone LLC | Human antibodies specific to kdr and uses thereof |
EP1482964B1 (en) * | 2002-03-08 | 2011-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of egfr transactivation inhibitors in human cancer |
WO2003079997A2 (en) * | 2002-03-21 | 2003-10-02 | Cayman Chemical Company | Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma |
JPWO2003101491A1 (ja) * | 2002-06-03 | 2005-09-29 | 三菱ウェルファーマ株式会社 | Her2又は/及びEGFR発現又は活性化対象に用いる予防又は/及び治療剤 |
EP1539236A4 (en) * | 2002-07-03 | 2007-07-18 | Univ Pennsylvania | COMPOSITIONS, METHODS AND KITS RELATING TO ANTIPLATELET AUTOANTIBODIES AND THEIR INHIBITORS |
PL374586A1 (en) * | 2002-10-10 | 2005-10-31 | Merck Patent Gmbh | Bispecific anti-erb-b antibodies and their use in tumor therapy |
US7638605B2 (en) | 2003-05-01 | 2009-12-29 | ImClone, LLC | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
PT1687338E (pt) * | 2003-11-07 | 2011-01-20 | Ablynx Nv | Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações |
DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
US20070172475A1 (en) * | 2004-02-12 | 2007-07-26 | Susanne Matheus | Highly concentrated, liquid formulations of anti-egfr antibodies |
TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
JP5835204B2 (ja) | 2012-12-20 | 2015-12-24 | 信越化学工業株式会社 | レジスト材料及びこれを用いたパターン形成方法 |
-
2005
- 2005-03-21 DK DK05732383.4T patent/DK1735348T3/da active
- 2005-03-21 RU RU2006137060/13A patent/RU2402569C2/ru not_active IP Right Cessation
- 2005-03-21 MX MXPA06010715A patent/MXPA06010715A/es active IP Right Grant
- 2005-03-21 PT PT05732383T patent/PT1735348E/pt unknown
- 2005-03-21 WO PCT/US2005/009583 patent/WO2005090407A1/en active Application Filing
- 2005-03-21 CA CA2560305A patent/CA2560305C/en not_active Expired - Fee Related
- 2005-03-21 AU AU2005224267A patent/AU2005224267B2/en not_active Ceased
- 2005-03-21 PL PL05732383T patent/PL1735348T3/pl unknown
- 2005-03-21 ES ES05732383T patent/ES2387809T3/es active Active
- 2005-03-21 CN CN201210509997.4A patent/CN103007279B/zh not_active Expired - Fee Related
- 2005-03-21 US US10/593,804 patent/US7598350B2/en active Active
- 2005-03-21 JP JP2007504185A patent/JP4734319B2/ja active Active
- 2005-03-21 EP EP05732383A patent/EP1735348B1/en active Active
- 2005-03-21 EP EP10176938A patent/EP2332990A1/en not_active Withdrawn
-
2012
- 2012-08-06 CY CY20121100704T patent/CY1113037T1/el unknown
-
2016
- 2016-05-20 CY CY2016016C patent/CY2016016I1/el unknown
- 2016-05-31 LU LU93093C patent/LU93093I2/fr unknown
- 2016-06-01 LT LTPA2016020C patent/LTC1735348I2/lt unknown
- 2016-06-14 NL NL300819C patent/NL300819I2/nl unknown
- 2016-06-14 HU HUS1600030C patent/HUS000495I2/hu unknown
Also Published As
Publication number | Publication date |
---|---|
CN103007279A (zh) | 2013-04-03 |
HUS000495I2 (hu) | 2021-03-29 |
ES2387809T3 (es) | 2012-10-02 |
CN103007279B (zh) | 2017-01-11 |
HUS1600030I1 (hu) | 2016-07-28 |
NL300819I2 (es) | 2016-07-21 |
LTC1735348I2 (lt) | 2017-11-10 |
LU93093I2 (fr) | 2016-08-01 |
WO2005090407A1 (en) | 2005-09-29 |
EP1735348B1 (en) | 2012-06-20 |
AU2005224267A1 (en) | 2005-09-29 |
CA2560305A1 (en) | 2005-09-29 |
CA2560305C (en) | 2016-07-05 |
PL1735348T3 (pl) | 2012-11-30 |
CY2016016I2 (el) | 2016-12-14 |
RU2006137060A (ru) | 2008-04-27 |
JP2008500815A (ja) | 2008-01-17 |
PT1735348E (pt) | 2012-07-24 |
US20070264253A1 (en) | 2007-11-15 |
DK1735348T3 (da) | 2012-07-16 |
RU2402569C2 (ru) | 2010-10-27 |
US7598350B2 (en) | 2009-10-06 |
AU2005224267B2 (en) | 2011-07-21 |
CY2016016I1 (el) | 2016-12-14 |
JP4734319B2 (ja) | 2011-07-27 |
WO2005090407A8 (en) | 2005-12-01 |
EP2332990A1 (en) | 2011-06-15 |
EP1735348A1 (en) | 2006-12-27 |
CY1113037T1 (el) | 2016-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA06010715A (es) | Anticuerpo del receptor del factor de crecimiento humano anti-epidermico. | |
WO2003075840A3 (en) | Human antibodies specific to kdr and uses thereof | |
NZ592215A (en) | c-MET ANTIBODIES | |
DK1565489T3 (da) | Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet | |
NO2017032I1 (no) | bezlotoksumab | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
ATE476992T1 (de) | Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper | |
ATE530195T1 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
AR084210A1 (es) | PROTEINAS DE UNION AL TNF-a | |
ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
WO2008066691A3 (en) | Tes7 and antibodies that bind thereto | |
EA200700876A1 (ru) | Агенты, специфически связывающие ангиопоэтин-2 | |
MX2015012540A (es) | Ratón de cadena ligera común. | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
NZ596381A (en) | Targeted binding agents directed to pdgfr-alpha and uses thereof | |
ATE504602T1 (de) | Für humane matriptase spezifische bindungsproteine | |
MX2022000174A (es) | Anticuerpos monoclonales que se enlazan a egfrviii y sus usos. | |
TH83706A (th) | แอนติ-5t4 แอนติบอดีที่ถูกฮิวมาไนซ์และคอนจูเกตของแอนติ-5t4 แอนติบอดี/คาลิซีอะไมซิน | |
TH83706B (th) | แอนติ-5t4 แอนติบอดีที่ถูกฮิวมาไนซ์และคอนจูเกตของแอนติ-5t4 แอนติบอดี/คาลิซีอะไมซิน |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status | ||
FG | Grant or registration |